DANIEL L. KISNER, M.D. - Corporate Board Profile

DYNAVAX TECHNOLOGIES CORP

Filing Date	Source Excerpt
2014-04-28	Daniel L. Kisner, M.D. 67 Director ... Our Board has three committees: an Audit Committee, a Compensation Committee and a Nominating and Governance Committee ... The following table shows for the fiscal year ended December 31, 2013, certain information with respect to the compensation of all non-employee directors of the Company: Daniel L. Kisner, M.D. Fees Earned or Paid in Cash $54,500 Options and Awards Granted $44,625 Total $99,125
2015-04-21	Daniel L. Kisner, M.D. 68 Director ... Dr. Kisner has been a member of our Board since July 2010. ... The following table shows for the fiscal year ended December 31, 2014, certain information with respect to the compensation of all non-employee directors of the Company: Daniel L. Kisner, M.D. $57,000 fees earned or paid in cash, $22,901 options and awards, total $79,901.
2016-04-22	Daniel L. Kisner, M.D. 69 Director ... Our Compensation Committee is composed of three directors: Ms. Phillips (Chairperson) and Drs. Kisner and Cano ... Our Board has three standing committees: an Audit Committee, a Compensation Committee and a Nominating and Governance Committee ... The following table shows for the fiscal year ended December 31, 2015, certain information with respect to the compensation of all non-employee directors of the Company: Daniel L. Kisner, M.D. $57,000 Fees Earned or Paid in Cash, $294,558 Option Awards, $351,558 Total.
2017-04-21	Daniel L. Kisner, M.D. 70 Director ... Our Compensation Committee is composed of three directors: Ms. Phillips (Chairperson) and Drs. Cano and Kisner ... The following table shows for the fiscal year ended December 31, 2016, certain information with respect to the compensation of all non-employee directors of the Company: Daniel L. Kisner, M.D. $57,000 Fees Earned or Paid in Cash, $70,692 Option Awards, $127,692 Total.
2017-07-10	Daniel L. Kisner, M.D., Director
2018-04-20	Daniel L. Kisner, M.D. 71 Director ... Our Compensation Committee is composed of three directors: Ms. Phillips (Chairperson) and Drs. Kisner and Cano ... Our Nominating and Governance Committee is composed of three directors: Drs. Kisner (Chairperson) and Cano, and Mr. Ricciardi ... The following table shows for the fiscal year ended December 31, 2017, certain information with respect to the compensation of all non-employee directors of the Company: Daniel L. Kisner, M.D. $57,000 $29,203 $86,203
2019-04-22	Our Board presently has eight members. There are three directors in the class whose term of office expires in 2019: Dennis A. Carson, M.D., Eddie Gray, and Laura Brege, each of whom is a nominee for director and currently a director of the Company. Dr. Carson, Mr. Gray and Ms. Brege were previously elected by the stockholders in 2016. If each nominee is elected at the Annual Meeting, each of these nominees will serve until the 2022 Annual Meeting and until his or her successor is elected and has qualified, or, if sooner, until the director's death, resignation or removal. We have a policy encouraging our directors' attendance at our annual meetings. There were six directors in attendance at our 2018 Annual Meeting. Directors are elected by a plurality of the votes of the holders of shares present in person or represented by proxy and entitled to vote on the election of directors. The three nominees receiving the highest number of affirmative votes will be elected. Shares represented by executed proxies will be voted, if authority to do so is not withheld, for the election of the nominees named below. Although the election of directors at the Annual Meeting is uncontested and directors are elected by a plurality of votes cast, and we therefore anticipate that each of the named nominees for director will be elected at the Annual Meeting, under our Corporate Governance Guidelines, any nominee for director is required to submit an offer of resignation for consideration by the Nominating and Corporate Governance Committee if such nominee for director (in an uncontested election) receives a greater number of "Withhold" votes than "For" votes. In such case, the Nominating and Corporate Governance Committee will then consider all of the relevant facts and circumstances and recommend to the Board the action to be taken with respect to such offer of resignation. For more information on this policy see the section entitled "Corporate Governance." If any nominee becomes unavailable for election as a result of an unexpected occurrence, your shares will be voted for the election of a substitute nominee proposed by our Board. Each person nominated for election has agreed to serve if elected. Our Board has no reason to believe that any nominee will be unable to serve. Our Board has three standing committees: an Audit Committee, a Compensation Committee and a Nominating and Governance Committee. The following table provides membership and meeting information for fiscal year 2018 for each of the Board committees: Name Audit Compensation Nominating Daniel L. Kisner, M.D. X X * ... The following table shows for the fiscal year ended December 31, 2018, certain information with respect to the compensation of all non-employee directors of the Company: Name Fees Earned or Paid in Cash Option Awards Total Daniel L. Kisner, M.D. $ 57,000 $ 156,767 $ 213,767
2020-04-17	Daniel L. Kisner, M.D. Dr. Kisner has been a member of our Board since July 2010. From 2003 to 2010, Dr. Kisner served as a partner at Aberdare Ventures and prior to that as President and CEO of Caliper Technologies, leading its evolution from a start-up focused on microfluidic lab-on-chip technology to a publicly traded, commercial organization. Prior to Caliper, he was the President and Chief Operating Officer of Isis Pharmaceuticals, Inc., a biomedical pharmaceutical company. Previously, Dr. Kisner was Division Vice President of Pharmaceutical Development for Abbott Laboratories and Vice President of Clinical Research and Development at SmithKline Beckman Pharmaceuticals. In addition, he held a tenured position in the Division of Oncology at the University of Texas, San Antonio School of Medicine and is certified by the American Board of Internal Medicine in Internal Medicine and Medical Oncology. Additionally, he is currently serving on the boards of Conatus Pharmaceuticals, Inc., a biotechnology company, and Zynerba Pharmaceuticals, a biotechnology company. Dr. Kisner previously served as Chairman of the board for Tekmira Pharmaceuticals, a biopharmaceutical company, until March 2015, and as a director of Lpath, Inc., a medical device company. He holds a B.A. from Rutgers University and an M.D. from Georgetown University. Our Board believes that Dr. Kisner’s background with larger, complex technology-based organizations as well as his significant experience with corporate transactions, including investing in venture-backed life science companies provides the Board with insights for setting strategy of the Company and qualifies him to be nominated as a director.
2021-04-16	Daniel L. Kisner, M.D. Dr. Kisner has been a member of our Board since July 2010. ... Our Board believes that Dr. Kisner’s background with larger, complex technology-based organizations as well as his significant experience with corporate transactions, including investing in venture-backed life science companies provides the Board with insights for setting strategy of the Company and qualifies him to serve as a director. ... The following table shows for the fiscal year ended December 31, 2020, certain information with respect to the cash compensation of all non-employee directors of the Company: ... Daniel L. Kisner, M.D. Fees Earned or Paid in Cash $57,000, Option Awards $83,168, Total $140,168.
2022-04-14	Dr. Kisner has been a member of our Board since July 2010... He is certified by the American Board of Internal Medicine in Internal Medicine and Medical Oncology... We believe that Dr. Kisner’s background with larger, complex technology-based organizations as well as his significant experience with corporate transactions, including investing in venture-backed life science companies provides the Board with insights for setting strategy of the Company and qualifies him to serve as a director.
2023-04-13	Daniel L. Kisner, M.D. Dr. Kisner has been a member of our Board since July 2010. ... Our Board believes that Dr. Kisner’s background with larger, complex technology-based organizations as well as his significant experience with corporate transactions, including investing in venture-backed life science companies provides the Board with insights for setting strategy of the Company and qualifies him to be nominated as a director.
2024-04-11	Daniel L. Kisner, M.D. Dr. Kisner has been a member of our Board since July 2010. ... Our Board believes that Dr. Kisners background with larger, complex technology-based organizations as well as his significant experience with corporate transactions, including investing in venture-backed life science companies, provides the Board with insights for setting strategy of the Company and qualifies him to serve on our Board.